Ameriprise’s Jade Biosciences JBIO Stock Holding History

Ameriprise’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-187,254	Closed	-$2.89M	–	4060
2025 Q4	$2.89M	Buy	+187,254	New	+$2.2M	﹤0.01%	2801

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise's JBIO Position: Q1 2026 in Review

Ameriprise sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 187,254 shares — an estimated $2.89M sold.

Ameriprise first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $2.89M in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

Ameriprise reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 187,254 Jade Biosciences shares in Q1 2026, an estimated $2.89M.
Ameriprise first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
Ameriprise's Jade Biosciences position peaked at $2.89M in Q4 2025.
120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.